Diabetic fibrosis.

Area of Science:

• Cellular and Molecular Medicine
• Endocrinology
• Pathology

Background:

• Diabetes mellitus (type 1 and type 2) is a major cause of morbidity and mortality, primarily due to organ-damaging complications.
• Fibrosis, characterized by excessive extracellular matrix deposition, is a common feature of advanced diabetes, contributing to organ dysfunction.
• Key metabolic derangements in diabetes, including hyperglycemia, lipotoxicity, and insulin resistance, initiate and perpetuate fibrotic responses across various tissues.

Purpose of the Study:

• To review the cellular and molecular mechanisms underlying fibrosis in diabetes.
• To elucidate the links between metabolic dysregulation and fibrogenic activation.
• To discuss organ-specific differences in diabetic fibrosis and explore anti-fibrotic therapy potential.

Main Methods:

• Literature review of existing research on diabetic fibrosis.
• Analysis of cellular and molecular pathways involved in fibrotic processes.
• Synthesis of information on the impact of hyperglycemia, lipotoxicity, and insulin resistance on fibrosis.

Main Results:

• Hyperglycemia and related metabolic factors activate multiple fibrogenic pathways, including oxidative stress, growth factor signaling (e.g., TGF-β, PDGFs), inflammation, and advanced glycation end-product (AGE) formation.
• Fibroblasts, immune cells, vascular cells, and potentially epithelial/endothelial cells adopt a fibrogenic phenotype.
• While common pathways exist, fibrosis severity varies, with heart, kidney, and liver being particularly susceptible.

Conclusions:

• Diabetic fibrosis is a complex process driven by metabolic perturbations activating diverse cellular and molecular pathways.
• Targeting these fibrogenic pathways presents therapeutic opportunities for mitigating diabetes-associated organ damage.
• Further research is needed to address organ-specific differences and optimize anti-fibrotic strategies for diabetic patients.